Trends Immunol. 2024 Nov 21:S1471-4906(24)00279-5. doi: 10.1016/j.it.2024.11.008. Online ahead of print.
ABSTRACT
A recent study by Ascic et al. demonstrates that in situ reprogramming of tumor cells into conventional dendritic cell (cDC)-like cells using viral-PIB transcription factors creates an immunogenic tumor microenvironment with T cell recruitment and activation. The study highlights the potential of tumor-specific cancer immunotherapy using in vivo reprogrammed cDCs.
PMID:39578119 | DOI:10.1016/j.it.2024.11.008